A 62-year-old woman with a history of hypertension and dyslipidemia presents with a 2-month history of exertional chest discomfort. Stress ECG shows ST-segment depression in leads II, III, and aVF, consistent with inferior wall ischemia. Coronary angiography reveals 70% stenosis of the right coronary artery. She is started on dual antiplatelet therapy, a statin, and an ACE inhibitor. For antianginal therapy, she is prescribed diltiazem (a non-dihydropyridine calcium channel blocker) 120 mg twice daily. After 1 week, she reports excellent symptom relief. However, she develops fatigue, dyspnea on mild exertion, and a persistent dry cough. On examination, heart rate is 48/min, blood pressure is 110/68 mmHg, and lung auscultation reveals bibasal crackles. Echocardiography shows an ejection fraction of 35% (previously 50%). What is the most likely explanation for her clinical deterioration?

Explanation

## Clinical Analysis ### Presentation Summary - **Baseline:** EF 50% (normal), stable on diltiazem monotherapy - **After 1 week:** EF 35% (severely reduced), bradycardia (HR 48), dyspnea, crackles, fatigue - **Timeline:** Acute deterioration temporally related to diltiazem initiation - **No evidence of:** acute MI (no chest pain, no troponin elevation), angioedema (no airway involvement), progressive CAD (symptoms improved on diltiazem) ## Mechanism of Diltiazem Toxicity Diltiazem is a **non-dihydropyridine calcium channel blocker** with potent **negative inotropic** and **negative chronotropic** effects. ```mermaid flowchart TD A[Diltiazem initiated]:::action --> B[Blocks L-type Ca2+ channels<br/>in myocardium]:::outcome B --> C[Reduced intracellular Ca2+]:::outcome C --> D[Decreased contractility<br/>Decreased HR]:::outcome D --> E{Underlying LV dysfunction?}:::decision E -->|No| F[Tolerated well]:::outcome E -->|Yes| G[Acute decompensation]:::urgent G --> H[Pulmonary edema<br/>Cardiogenic shock]:::urgent ``` ## Key Point: **Non-dihydropyridine CCBs (diltiazem, verapamil) are contraindicated in patients with reduced ejection fraction or heart failure.** They worsen systolic dysfunction and precipitate acute decompensation. ## High-Yield: **Diltiazem causes:** - Negative inotropic effect (reduces contractility) - Negative chronotropic effect (slows heart rate) - AV nodal conduction delay These effects are **beneficial in angina** (reduce myocardial oxygen demand) but **harmful in systolic HF** (worsen pump function). ## Differential Diagnosis of Deterioration | Diagnosis | Key Finding | Why Excluded | |-----------|-------------|---------------| | **Diltiazem-induced HF** | Acute ↓EF + bradycardia after drug start | **BEST FIT** — temporal relationship, mechanism, findings | | RV infarction | Hypotension + elevated JVP | BP normal (110/68); no RV-specific ECG changes | | Angioedema | Airway swelling, stridor | No respiratory distress; crackles suggest pulmonary edema, not angioedema | | Progressive CAD | Recurrent chest pain | Chest pain resolved; symptoms are HF, not angina | ## Clinical Pearl: Patients with **occult or borderline LV systolic dysfunction** may tolerate diltiazem initially but decompensate within days to weeks as the negative inotropic effect accumulates. A baseline EF of 50% (low-normal) may have represented compensated dysfunction. ## Management 1. **Discontinue diltiazem immediately** 2. Initiate ACE inhibitor uptitration (already started; optimize dose) 3. Add beta-blocker (carvedilol or metoprolol) — **positive inotropic effect via β2-mediated vasodilation** 4. Consider aldosterone antagonist if EF remains <35% 5. Diuretics for pulmonary edema 6. For angina: use **dihydropyridine CCB** (amlodipine, nifedipine) or long-acting nitrate instead ## Warning: **Non-dihydropyridine CCBs + beta-blockers = severe bradycardia and AV block risk.** If beta-blocker is needed, use dihydropyridine CCB instead, or use diltiazem alone without beta-blocker.